Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer
Open Access
Abstract
Human papillomavirus (HPV)-associated oropharyngeal cancer has a better prognosis than other head and neck cancers. However, rates of recurrence and metastasis are similar and the prognosis of recurrent or metastatic HPV-associated oropharyngeal cancer is poor. Near-infrared photoimmunotherapy (NIR-PIT) is a treatment involving administration of a photosensitizer (IRDye®700DX) conjugated to a monoclonal antibody followed by activation with near-infrared light illumination. It is a highly tumor-specific therapy with minimal toxicity in normal tissues. Moreover, NIR-PIT is expected to have not only direct effects on a treated lesion but also immune responses on untreated distant lesions. NIR-PIT with cetuximab-IR700 (AlluminoxTM) has been in routine clinical use since January 2021 for unresectable locally advanced or locally recurrent head and neck cancer in patients that have previously undergone radiotherapy in Japan. NIR-PIT for head and neck cancer (HN-PIT) is expected to provide a curative treatment option for the locoregional recurrent or metastatic disease after radiotherapy and surgery. This article reviews the mechanism underlying the effect of NIR-PIT and recent clinical trials of NIR-PIT for head and neck cancers, treatment-specific adverse events, combination treatment with immune checkpoint inhibitors, illumination approach and posttreatment quality of life, and provides a case of series of two patients who receive NIR-PIT for oropharyngeal cancer at our institution.Keywords
This publication has 52 references indexed in Scilit:
- Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapyBMC Cancer, 2012
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from “Silent” to ImmunogenicCancer Research, 2007
- Salvage Re-Irradiation for Recurrent Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survivalInternational Journal of Cancer, 2000